Posted by Michael Wonder on 20 Nov 2021
Reata Pharmaceuticals receives fast track designation from the FDA for omaveloxolone for the treatment of Friedreich’s ataxia
18 November 2021 - Reata Pharmaceuticals today announced the U.S. FDA has granted fast track designation for omaveloxolone for the treatment of Friedreich’s ataxia.
Omaveloxolone is an investigational, oral, once-daily, activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signalling.
